23andMe logo

Postdoctoral Fellow, Cardiometabolic Disorders - 23andMe

View Company Profile
Job Title
Postdoctoral Fellow, Cardiometabolic Disorders
Job Location
South San Francisco, CA
Job Description

Who We Are

23andMe, the leading consumer genetics and research company, has accumulated a wealth of genotypic and phenotypic information from participants committed to improving human health through advances in genomics. Our Therapeutics team in South San Francisco leverages this data to discover and develop new treatments that can offer significant benefits for patients with serious, unmet medical needs.

This dedicated research and drug development group identifies novel targets using 23andMe's genetic database and performs preclinical research to advance programs towards clinical development. We currently have programs across several therapeutic areas, including but not limited to oncology, immunology, and cardiovascular diseases. More information about our Therapeutics team is available at https://therapeutics.23andme.com/.

23andMe has committed to the initiation of a postdoctoral fellowship program that would create opportunities to utilize the 23andMe human genetics platform to conduct cutting-edge science and explore novel biology.  Six inaugural fellowships are being offered within the Therapeutics division.  The postdoctoral fellow will be expected to focus on innovative, genetics or biological research questions with a goal of presenting their work externally at scientific meetings and publishing in top-ranked peer-reviewed journals.  This opportunity will allow postdoctoral fellows to gain exposure to the biotechnology industry to either pursue a career in industry or bring the industry perspective back to an academic career. The fellowships are for a three-year period, with an optional one-year extension. 


Project Summary

23andMe Therapeutics Research is seeking a Postdoctoral Fellow to study disease mechanisms involved in Cardiometabolism. The successful candidate will be able to utilize computational biology tools to mine the vast 23andMe genetic database. 23andMe, the leading consumer genetics and research company, has amassed a wealth of genotypic and phenotypic information from more than 10M participants. Drawing from insights from human genetics and physiology, the fellow will characterize genetic variants for impact on protein function. The initial proposed project will be to study genetic variants associated with diseases associated with cardiometabolism, but research focus may alter depending on the science and the Fellow’s interest.  Experimental approaches include biochemical, cell biological and in vivo rodent models.  The candidate will have an advanced degree in biology, biochemistry, biophysics or chemical biology. The preferred candidate will have expertise in chemical biology, in order to apply state of the art chemistry to biological problems. The Fellow will be part of the inaugural class of Postdoctoral Fellows at 23andMe,  will work in a multidisciplinary research team and will help shape the future of the program. The 23andMe Postdoctoral Fellow will be part of a vibrant scientific community in the San Francisco Bay Area.  


What You’ll Do

  • Analyze genetic variants associated with Cardiometabolic disease. Utilize computational methods to extract deep phenotypic information correlated to genetic variation
  • Establish necessary biochemical (eg. protein interaction studies) and cell biological models (eg. 3D kidney culture model, primary cells) to test and understand the impact of genetic variants on physiological function. 
  • Develop and characterize rodent models in order to uncover the impact of genetic LoF and GoF on disease progression in vivo. Design, implement and test strategies to alter gene function to understand potential for clinical translation
  • Communicate and collaborate effectively with colleagues to drive progression of the project.
  • Publish in high-profile scientific journals.


What You’ll Bring

  • Ph.D. in Biology, Molecular Biology, Cell Biology, Genetics, Chemical Biology or a related field.
  • Curiosity, drive, energy and flexibility to explore Cardiometabolic disease
  • Successful record of high-quality publications
  • Excellent organizational, verbal and written communication skills with the ability to work independently and proactively within a team environment.
  • Proven ability to work on a cross-functional team and successfully lead a project to decision points.


Strongly Preferred

  • Experience with biochemical and cell-based assay and implementing novel technologies
  • Experience with genome-wide association analyses.
  • Experience with chemical biology or implementing chemical techniques to explore biological problems



Dr. Dan Lin’s Bio

Dan joined 23andMe as the Director of Cardiometabolism in 2021. He was attracted to 23andMe for its potential to uncover novel and unexpected insights into human biology, and its mission to transform healthcare. His lab studies biological mechanisms in disease with a focus on drug discovery. Their remit is extensive: exploring novel pathways using human genetics in many areas of cardiometabolic disease. His passion is to draw upon these genetic insights, and through engineering, testing, and pharmacology, to turn them into therapeutics. His group uses cell biological and biochemical techniques to decipher protein function and establish experimental assays to screen for drug candidates, and in vivo models to demonstrate improvement in health. Dan has published work spanning TRP ion channels, polycystic kidney disease and GPCR drugs. He completed his Ph.D. in Biology at MIT, followed by a Postdoctoral Fellowship at Tularik. Prior to 23andMe, Dan spent 17 years as a scientific leader of numerous drug discovery teams at Amgen, where he advanced dozens of programs through preclinical testing and was an active member of external outreach efforts.


About Us

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.

At 23andMe, we value a diverse, inclusive workforce and we provide equal employment opportunity for all applicants and employees. All qualified applicants for employment will be considered without regard to an individual’s race, color, sex, gender identity, gender expression, religion, age, national origin or ancestry, citizenship, physical or mental disability, medical condition, family care status, marital status, domestic partner status, sexual orientation, genetic information, military or veteran status, or any other basis protected by federal, state or local laws.  If you are unable to submit your application because of incompatible assistive technology or a disability, please contact us at accommodations-ext@23andme.com. 23andMe will reasonably accommodate qualified individuals with disabilities to the extent required by applicable law.

Please note: 23andMe does not accept agency resumes and we are not responsible for any fees related to unsolicited resumes. Thank you.

23andMe Headquarters Location

Mountain View, CA

23andMe Company Size

Between 500 - 1,000 employees

23andMe Founded Year


23andMe Funding Rounds

  • Post Ipo Equity

    $250,000,000 USD

  • Series F

    $82,500,000 USD

  • Corporate Round

    $300,000,000 USD

  • Series F

    $250,000,000 USD

  • Grant

    $1,700,000 USD

  • Series E

    $115,000,000 USD

  • Grant

    $1,400,000 USD

  • Series D

    $50,000,000 USD

  • Series C

    $9,000,000 USD

  • Series C

    $22,220,289 USD

  • Series B

    $14,200,000 USD

  • Series B

    $13,600,000 USD

  • Series A

    $8,953,320 USD